- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00763347
Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus
A Phase 2, Double-Blind Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate Treatment With SYR-619 in Subjects With Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% is type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes, and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected, placing an ever increasing burden on families and the health care system.
SYR-619 is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase IV is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.
The aim of this study is to evaluate the dose-response efficacy, safety and tolerability of treatment with SYR-619 in subjects with type 2 diabetes who do not previously achieve adequate glycemic control with lifestyle modification (diet/exercise) or metformin or sulfonylurea oral antidiabetic monotherapy.
Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be about 14 Weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs including sitting and standing blood pressure and pulse, body height and weight, physical examinations, electrocardiogram.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, with a historical diagnosis of type 2 diabetes mellitus.
- Treatment for diabetes with either lifestyle modification or metformin or sulfonylurea alone for at least the 2 months prior to Screening; and a stable dose of either metformin or sulfonylurea for at least 12 weeks prior to randomization for subjects receiving metformin or sulfonylurea at Screening.
- Those subjects receiving metformin or sulfonylurea monotherapy at randomization must have been at least 75% compliant with their metformin or sulfonylurea regimen during the run in/stabilization period, as assessed by subject diary and investigator assessment.
- No treatment with antidiabetic agents other than metformin alone or sulfonylurea alone within the 3 months prior to Screening.
- Glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive, and a fasting plasma glucose <275 mg/dL (<15.27 mmol/L) at the Week -1 visit.
- Body mass index ≥23 and ≤45 kg/m2.
- Fasting C-peptide concentration ≥0.8 ng/mL (≥0.26 nmol/L). (If this screening criterion is not met, the subject still qualifies if C-peptide ≥1.5 ng/mL [≥0.50 nmol/L] after a challenge test).
- If regular use of other non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening. However, as needed use of prescription or over-the-counter medications is allowed at the discretion of the investigator.
- Systolic blood pressure <160 mm Hg and diastolic pressure <100 mm Hg.
- Hemoglobin ≥12 g/dL (≥120 gm/L) for males and ≥10 g/dL (≥100 gm/L) for females.
- Alanine aminotransferase ≤3 x upper limit of normal.
- Serum creatinine <1.5 mg/dL (<133 micromol/L) for males and <1.4 mg/dL (<124 micromol/L) for females.
- Urine albumin/creatinine ratio of <1000 μg/mg (113 mg/mol) at Screening. If elevated, the subject may be rescreened within 1 week.
- Thyroid-stimulating hormone level ≤ the upper limit of the normal range and the subject has normal thyroid function (clinically euthyroid)
- A female subject of childbearing potential who is sexually active must agree to use adequate contraception, and must be neither pregnant nor lactating from Screening and throughout the duration of the study.
- Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.
- No major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
Exclusion Criteria:
- Concurrently treated with combined metformin and sulfonylurea antidiabetic therapy.
- History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening.
- History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
- History of treated diabetic gastric paresis.
- New York Heart Association Class III or IV heart failure regardless of therapy.
- Currently treated subjects who are stable at Class I or II are candidates for the study.
- History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.
- History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
- History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
- History of a psychiatric disorder that in the investigator's opinion will affect the subject's ability to participate in the study.
- History of alcohol abuse or substance abuse within the 2 years prior to Screening.
The subject is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Treatment with antidiabetic agents other than study drug or metformin or sulfonylurea is not allowed within the 3 months prior to Screening and through the completion of the end-of-treatment/early termination procedures.
- Treatment with weight-loss drugs, any investigational antidiabetic drugs, or oral or systemically injected glucocorticoids is not allowed from 3 months prior to randomization through the completion of the end-of-treatment/early termination procedures.
- Receipt of any investigational drug within the 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within the 3 months prior to Screening.
- Prior treatment in an investigational study of SYR-619 or alogliptin.
- The subject has a known hypersensitivity to any compound related to SYR-619 or alogliptin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo QD
|
SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
|
Experimental: SYR-619 12.5 mg QD
|
SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
|
Experimental: SYR-619 50 mg QD
|
SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
|
Experimental: SYR-619 100 mg QD
|
SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
|
Experimental: SYR-619 200 mg QD
|
SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
|
Active Comparator: Alogliptin 25 mg QD
|
Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in glycosylated hemoglobin.
Time Frame: Week 12 or Final Visit..
|
Week 12 or Final Visit..
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in glycosylated hemoglobin.
Time Frame: Weeks 4, 8 and 12 or Final Visit.
|
Weeks 4, 8 and 12 or Final Visit.
|
Change from baseline in fasting plasma glucose.
Time Frame: Weeks: 1, 2, 4, 8 and 12 or Final Visit.
|
Weeks: 1, 2, 4, 8 and 12 or Final Visit.
|
Change from baseline in 1,5 anhydroglucitol.
Time Frame: Weeks 2, 4, 8 and 12 or Final Visit.
|
Weeks 2, 4, 8 and 12 or Final Visit.
|
Change from baseline in proinsulin.
Time Frame: Weeks 4, 8 and 12 or Final Visit.
|
Weeks 4, 8 and 12 or Final Visit.
|
Change from baseline in insulin.
Time Frame: Weeks 4, 8 and 12 or Final Visit.
|
Weeks 4, 8 and 12 or Final Visit.
|
Change from baseline in proinsulin/insulin ratio.
Time Frame: Weeks 4, 8 and 12 or Final Visit.
|
Weeks 4, 8 and 12 or Final Visit.
|
Change from baseline in C-peptide.
Time Frame: Weeks 4, 8 and 12 or Final Visit.
|
Weeks 4, 8 and 12 or Final Visit.
|
Homeostasis model assessment insulin resistance.
Time Frame: Weeks 4, 8 and 12 or Final Visit.
|
Weeks 4, 8 and 12 or Final Visit.
|
Homeostasis model assessment beta-cell function.
Time Frame: Weeks 4, 8 and 12 or Final Visit.
|
Weeks 4, 8 and 12 or Final Visit.
|
Incidence of marked hyperglycemia (fasting plasma glucose ≥200 mg/dL [≥11.10 mmol/L]).
Time Frame: Weeks 1, 2, 4, 8 and 12 or Final Visit.
|
Weeks 1, 2, 4, 8 and 12 or Final Visit.
|
Incidence of rescue.
Time Frame: Weeks 1, 2, 4, 8 and 12 or Final Visit.
|
Weeks 1, 2, 4, 8 and 12 or Final Visit.
|
Clinical response endpoint incidence of glycosylated hemoglobin ≤6.5%.
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
Clinical response endpoint incidence of glycosylated hemoglobin ≤7.0%.
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
Clinical response endpoint incidence of glycosylated hemoglobin improvement ≥1.0%.
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
Clinical response endpoint incidence of glycosylated hemoglobin improvement ≥1.5%.
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
Clinical response endpoint incidence of glycosylated hemoglobin improvement ≥2.0%.
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein cholesterol).
Time Frame: Weeks 4, 8, and 12 or Final Visit.
|
Weeks 4, 8, and 12 or Final Visit.
|
Postprandial area under the concentration-time curve and peak 2-hour values of plasma glucose, insulin and C-peptide during a 3-hour mixed-meal tolerance test in a subset of subjects.
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
Plasma concentration of SYR-619.
Time Frame: Week 8.
|
Week 8.
|
Physical examination findings (including a clinical examination of skin and digits).
Time Frame: At All Visits
|
At All Visits
|
Vital sign measurements.
Time Frame: At All Visits
|
At All Visits
|
Body temperature measurements.
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
12-lead electrocardiogram tracings.
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
Incidence of adverse events.
Time Frame: At All Visits
|
At All Visits
|
Incidence of hypoglycemia (blood glucose <60 mg/dL [<3.33 mmol/L]) in the presence of symptoms or blood glucose <50 mg/dL [<2.78 mmol/L]) regardless of symptoms).
Time Frame: At All Visits
|
At All Visits
|
Clinical laboratory evaluations (hematology and serum chemistry).
Time Frame: At All Visits
|
At All Visits
|
Clinical laboratory evaluation (urinalysis).
Time Frame: Week 12 or Final Visit.
|
Week 12 or Final Visit.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Alogliptin
Other Study ID Numbers
- 01-06-TL-SYR-619-003
- U1111-1124-2377 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Alogliptin
-
Kun-Ho YoonTakedaCompletedType 2 Diabetes MellitusKorea, Republic of
-
TakedaCompletedDiabetes MellitusUnited States, Australia, Brazil, Chile, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Netherlands, Poland, United Kingdom, Argentina, Dominican Republic
-
TakedaCompleted
-
TakedaCompletedDiabetes MellitusUnited States, Australia, Brazil, Chile, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Czech Republic, Germany, Hungary, Netherlands, Poland, Argentina
-
TakedaCompletedDiabetes MellitusUnited States, Australia, Brazil, Chile, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Czech Republic, Germany, Hungary, Netherlands, Poland, United Kingdom, Argentina
-
Kun-Ho YoonTakedaTerminated
-
TakedaCompletedDiabetes MellitusChina, Taiwan, Korea, Republic of, Malaysia
-
TakedaTerminatedDiabetes Mellitus, Type 2China, Hong Kong
-
TakedaCompletedDiabetes MellitusNetherlands, Sweden
-
Seoul National University HospitalUnknownType 2 Diabetes Mellitus